Compounds for inhibition of ceramide-mediated signal transduction
CA 2287484 A1 · Owner: The Regents Of The University Of California · Inventors: Carson, Dennis A.; Cottam, Howard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel, heterocyclic compounds having at least one ring nitrogen disclosed , side chains and, in some embodiments an oxygen ortho to the ring nitrogen , inhibit inflammatory responses associated with TNF-.alpha. and fibroblast proliferation in vivo and in vitro. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses in stimuli in vivo (particularly TN-.alpha.) are also described. The methods are expected to be of use …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 18, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 18, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 18, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.